Cencora Inc., a leading pharmaceutical distributor with a growing footprint in physician practice management through its Management Services Organization (MSO) platforms, reported its fiscal first-quarter 2026 results on February 4, 2026. The company announced the simultaneous closure of its acquisition of a 92% stake in OneOncology, creating a large-scale platform supporting community oncology and retina practices nationwide.
The earnings demonstrate Cencora’s progress in building a physician-centric services business alongside its core distribution operations. Specialty volumes remained strong, and the combined MSO footprint offers enhanced capabilities in clinical research, revenue cycle management and technology support for independent practices.
Specialty Distribution and MSO Performance Highlights:
Cencora’s U.S. Healthcare Solutions segment lead the growth, with revenue up 5% to $76.2 billion and operating income rising 21% to $831 million. Key drivers included a $1 billion (11%) increase in GLP-1 product sales, robust specialty volumes to health systems and physician practices and contributions from Retina Consultants of America (RCA). RCA, acquired in January 2025, outperformed expectations with higher patient volumes, active research enrollment, deployment of advanced imaging devices across practices and successful physician recruitment. These factors supported consolidated gross profit growth of 18% and margin expansion to 3.48% (up 37 basis points from 3.11% in the prior-year quarter).
The OneOncology transaction scales the MSO model, providing administrative and clinical support to community oncology providers. Management noted opportunities to share best practices across platforms, including RCA’s leadership in retina trials (representing more than one-third of U.S. research in the field) and strengths in data-driven insights.
Revenue and Profitability Trends:
Consolidated revenue increased 5.5% to $85.9 billion. Adjusted diluted EPS rose 9% to $4.08. Results reflected solid execution despite a prior oncology customer loss and temporary international operating income pressure from manufacturer price adjustment timing in a developing market.
Adjusted free cash flow was negative $2.4 billion due to seasonal working capital needs but improved year-over-year, with full-year guidance around $3 billion. Acquisition financing raised interest expense expectations to $480-500 million, prompting a pause on share repurchases for deleveraging.
2026 Outlook and Strategic Priorities:
Cencora raised several full-year metrics to incorporate OneOncology and ongoing specialty momentum:
- Consolidated revenue growth: 7-9%.
- Consolidated operating income growth: 11.5-13.5%.
- U.S. Healthcare Solutions operating income growth: 14-16%.
- Adjusted diluted EPS: $17.45-17.75 (reaffirmed).
Cencora CEO Robert Mauch emphasized the strategic fit of MSOs, stating they represent a natural extension of specialty distribution and GPO services while strengthening relationships with providers and manufacturers. He highlighted physician leadership in advanced therapies and early adoption of innovative treatments to improve patient access in community settings.
Cencora CFO James Cleary noted strong underlying U.S. performance even excluding acquisitions, driven by utilization trends and specialty sales, with the raised guidance reflecting confidence in execution.
Future Considerations in Physician Practice Management:
Cencora operates at the intersection of pharmaceutical distribution and physician enablement, a segment influenced by rising administrative complexity, value-based care shifts and specialty drug innovation. Its scaled MSO platform provides community practices with operational support without requiring full employment models.
The company continues portfolio assessment of non-core assets, with potential divestitures to focus resources on growth areas. While short-term dilution is possible from such moves, management expects long-term benefits. With financial flexibility post-deleveraging and raised outlook, Cencora remains positioned for additional transactions in oncology and specialty physician services, likely influencing consolidation activity in these high-growth fields through 2026 and beyond.
